# The Cooper Companies, Inc. (COO) Stock Analysis: Health Sector Innovator with 12.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-analysis-health-sector-innovator-with-12-3-upside-potential/4121258989
- Published: 2026-08-03T10:24:16+01:00
- Author: Madison Wilson

The Cooper Companies, Inc. (NYSE: COO) is making waves in the healthcare sector,
standing out in the competitive field of medical instruments and supplies. With 
a market capitalization of $14.1 billion and a diverse product portfolio, the company
operates through two key segments: CooperVision and CooperSurgical. These segments
cater not just to vision correction needs but also to women’s health and family 
care, offering products ranging from contact lenses to fertility and genomic services.

Currently priced at $72.32, Cooper Companies has experienced a stable yet varied
trading range over the past year, fluctuating between $58.98 and $84.32. Although
the latest price change was minimal, investors are keenly observing the company’s
trajectory. The forward P/E ratio is a notable 14.47, suggesting that the stock 
might be attractively priced relative to its expected earnings growth, despite the
absence of a trailing P/E ratio.

Revenue growth at 7.90% signals a robust expansion, although the lack of available
net income data may leave some investors cautious. The company’s earnings per share(
EPS) is reported at 1.18, with a modest return on equity (ROE) of 2.85%. A significant
highlight for the company is its free cash flow, which stands at an impressive $
424 million, underscoring its solid financial health and ability to reinvest in 
its business.

Cooper Companies does not currently offer a dividend yield, maintaining a payout
ratio of 0.00%. This might appeal to growth-focused investors who value reinvestment
in innovation over immediate income. Analyst sentiment reflects optimism, with 10
buy ratings and 6 hold ratings, and no sell ratings—a reassuring sign for prospective
shareholders. The analyst consensus sets the average target price at $81.21, indicating
a potential upside of 12.3% from the current price.

Technically, the stock’s 50-day moving average stands at $68.05, while the 200-day
moving average is slightly higher at $73.08. An RSI (14) of 63.08 suggests the stock
is approaching overbought territory, while a MACD of 0.97 and a signal line of 1.01
indicate a stable momentum.

Investors should consider Cooper Companies’ strategic position in the healthcare
market, leveraging its innovations in both vision care and reproductive health. 
With its comprehensive range of products and services, the company is well-placed
to address diverse consumer needs, which could drive future growth. Given its solid
financial footing and favorable analyst ratings, The Cooper Companies, Inc. looks
to be a compelling prospect for investors seeking exposure to a dynamic healthcare
innovator with a promising outlook.

Share on:
